Clinical Trial

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Name: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases — clinical trial record (NCT06941129)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-16.

Trial Details

NCT Number	NCT06941129
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions	Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV), Connective Tissue Disease-Associated Thrombocytopenia, SLE-ITP
Enrollment	12 participants
Start Date	2025-02-11
Primary Completion	2028-02-18 (estimated)
Study Completion	2028-03-18 (estimated)
Updated on ClinicalTrials.gov	2025-09-29